Cadrenal Therapeutics Inc (CVKD)

Feb 6, 2025, 9:00 AM EST - 16 days ago

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Feb 5, 2025, 9:00 AM EST - 17 days ago

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Jan 9, 2025, 8:44 AM EST - 6 weeks ago

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 31, 2024, 8:00 AM EST - 7 weeks ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Dec 18, 2024, 9:00 AM EST - 2 months ago

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Nov 19, 2024, 9:00 AM EST - 3 months ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Nov 12, 2024, 9:00 AM EST - 3 months ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Nov 7, 2024, 9:00 AM EST - 3 months ago

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Nov 1, 2024, 8:00 PM EDT - 4 months ago

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Oct 24, 2024, 9:00 AM EDT - 4 months ago

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Oct 23, 2024, 9:00 AM EDT - 4 months ago

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Sep 23, 2024, 4:15 PM EDT - 5 months ago

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Aug 22, 2024, 9:00 AM EDT - 6 months ago

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Aug 20, 2024, 9:00 AM EDT - 6 months ago

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Aug 20, 2024, 7:00 AM EDT - 6 months ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA ELUT EUDA GDTC GOSS GOVX IMRN

Aug 14, 2024, 9:00 AM EDT - 6 months ago

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Aug 7, 2024, 4:05 PM EDT - 7 months ago

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Aug 6, 2024, 9:00 AM EDT - 7 months ago

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

ABT

Jul 17, 2024, 9:00 AM EDT - 7 months ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Jun 11, 2024, 4:15 PM EDT - 9 months ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Jun 3, 2024, 9:00 AM EDT - 9 months ago

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

ABT

May 23, 2024, 9:00 AM EDT - 9 months ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 9, 2024, 9:00 AM EDT - 10 months ago

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

Apr 11, 2024, 4:30 PM EDT - 11 months ago

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Apr 9, 2024, 9:00 AM EDT - 11 months ago

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Mar 11, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Feb 26, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Feb 8, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Jan 31, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

Jan 24, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 4, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Dec 19, 2023, 9:00 AM EST - 1 year ago

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

Dec 12, 2023, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization

Nov 30, 2023, 4:15 PM EST - 1 year ago

Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023

Nov 9, 2023, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

Oct 9, 2023, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)

Aug 28, 2023, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update

Aug 1, 2023, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases

Jul 24, 2023, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

Jul 14, 2023, 3:02 PM EDT - 1 year ago

Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jul 12, 2023, 3:17 PM EDT - 1 year ago

Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jun 1, 2023, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston

May 10, 2023, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update

May 9, 2023, 4:30 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference

Mar 30, 2023, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update

Mar 9, 2023, 9:00 AM EST - 2 years ago

Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population

Feb 8, 2023, 9:00 AM EST - 2 years ago

Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023